IRON
$60.06-0.83 (-1.36%)
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United S...
Recent News
Evaluating Disc Medicine (IRON) After Recent Share Moves And Conflicting Valuation Signals
Event Overview and Immediate Context Disc Medicine (IRON) has drawn fresh attention after recent share price moves, with the stock up about 3% over the past day but showing a negative return over the past month and past 3 months. See our latest analysis for Disc Medicine. The latest 3.0% 1 day share price return and 2.8% 7 day share price return sit against weaker recent momentum, with the 30 day and 90 day share price returns both negative while the 1 year and 3 year total shareholder...
Biotech Stocks Rally on Departure of Polarizing FDA Official
Biotech investors have rarely united so strongly against a Food and Drug Administration official as they did against Vinay Prasad, who led the FDA's vaccines and related biological products division and blocked several rare-disease drugs from receiving accelerated approval. Prasad’s stance had weighed heavily on the stocks of companies developing the drugs. Now those stocks are rallying after FDA Commissioner Marty Makary said Friday in an interview that Prasad will be departing at the end of April.
What 3 recent FDA rejections reveal about shifts inside the agency
The FDA’s approval strategy has been difficult to pin down, but recent decisions provide clues for how some of the most volatile initiatives will play out.
Disc Medicine CFO Sells $720k Worth of Shares Amid FDA Rejection
This clinical-stage biopharmaceutical company recently had one of its treatments rejected for FDA approval. Now the company is cutting its workforce.
Disc Medicine (IRON) Is Up 8.6% After Wider 2025 Losses And New Shelf Registration - What's Changed
Disc Medicine, Inc. reported full-year 2025 results on 26 February 2026, with net loss rising to US$212.18 million and basic and diluted loss per share from continuing operations increasing to US$6.01 from US$3.96 a year earlier. On the same day, the company filed a US$108.71 million shelf registration for 1,625,179 common shares tied to its employee stock plans, underscoring ongoing funding needs as it advances multiple hematology programs through the clinic. We will now examine how Disc...